LEADS BIOLABS-B (09887) jumped more than 10% during morning trading session. As of press time, the stock was up 8.04% to HK$69.85 with a turnover of HK$76.91 million.

On the news front, LEADS BIOLABS recently announced that its independently developed opalatinib (LBL-024, anti-PD-L1/4-1BB bispecific antibody) has successfully completed the first patient enrollment in a Phase Ib/II clinical study (NCT07099430). The study will investigate opalatinib as monotherapy or in combination for the treatment of first-line advanced melanoma.

Notably, LBL-024 represents the world's first 4-1BB receptor-targeting therapy to reach the registration clinical stage for extrapulmonary neuroendocrine carcinoma, and is expected to potentially become the first approved drug for treating advanced extrapulmonary neuroendocrine carcinoma.

According to public information, LEADS BIOLABS currently has 14 drug candidates in its pipeline, with 6 having entered clinical stages, including 1 core product and 3 key products. The core product LBL-024 is a PD-L1 and 4-1BB bispecific antibody in registration clinical stage. The company is currently evaluating LBL-024's potential efficacy against advanced extrapulmonary neuroendocrine carcinoma, small cell lung cancer, biliary tract cancer, non-small cell lung cancer, and other solid tumors.